Plain-English translation of NCT04198766 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new drug called INBRX-106 that works by activating your immune system to fight cancer. The medication is being tested in two ways: as a single treatment, and combined with another immunotherapy drug called Keytruda. Researchers want to find the safest and most effective dose for people with various types of advanced cancer.
Many patients with advanced cancers stop responding to current standard treatments, leaving few options. This trial exists to see whether this new immune-boosting medication can help patients whose cancer is no longer controlled by available therapies.
You likely qualify if…
You likely don't qualify if…
You would receive regular infusions or injections of the medication at a clinic, with frequent doctor visits and blood tests to monitor your health and how well the treatment is working. Depending on which part of the study you join, you may receive the new drug alone, or in combination with Keytruda. The study is designed to last several months or longer, with ongoing visits to check for side effects and treatment response.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States